Evaluating the effect of oral clarithromycin on acute cutaneous leishmaniasis lesions compared with systemic glucantime

References

• Seyedi-Rashti M, Nadim A. Attempts to control zoonotic cutaneous leishmaniasis in the Isfahan area, Iran. Iran J Publ Health. 1974;2:199–203.
   Google Scholar
• Beaver PC, Jung RC, Cupp EW, et al. Clinical parasitology. Philadelphia (PA): Lea & Febiger; 1984.
   Google Scholar
• Sadeghian G, Ziaei H, Shirani-Bidabadi L, et al. Lupoid leishmaniasis due to Leishmania major with remaining large scars: report of 2 cases. East Mediterr Health J. 2010;16(3):344–345.
   PubMedGoogle Scholar
• Ranawaka RR, Weerakoon HS. Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. J Dermatolog Treat. 2010;21(5):286–293.
   PubMed Web of Science ®Google Scholar
• Alkhawajah A, Larbi E, Al-Gindan Y, et al. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration. Ann Trop Med Parasitol. 1997;91(8):899–906.
   PubMed Web of Science ®Google Scholar
• Nagaty I, Lashin A. Treatment of cutaneous leishmaniasis patients with pentostam via intralesion infiltration. J Egypt Soc Parasitol. 2000;30(1):177–182.
   PubMedGoogle Scholar
• Prata A, Silva-Vergara ML, Costa L, et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2003;36(1):65–69.
   PubMedGoogle Scholar
• Sazgarnia A, Zabolinejad N, Layegh P, et al. Antileishmanial activity of liposomal clarithromycin against leishmania major promastigotes. Iran J Basic Med Sci. 2012;15(6):1210–1214.
   PubMed Web of Science ®Google Scholar
• Chahed M, Ben SA, Louzir H, et al. Efficacy of intra-lesional glucantime in the treatment of zoonotic cutaneous leishmaniasis in basic health care conditions. Arch L'Inst Pasteur Tunis. 1998;76(1–4):13–18.
   Google Scholar
• Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg. 1994;88(1):92–94.
   PubMed Web of Science ®Google Scholar
• Soto J, Fuya P, Herrera R, et al. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis. 1998;26(1):56–58.
   PubMed Web of Science ®Google Scholar
• Soto J, Hernandez N, Mejia H, et al. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis. 1995;20(1):47–51.
   PubMed Web of Science ®Google Scholar
• Tallab TM, Bahamdam KA, Mirdad S, et al. Cutaneous leishmaniasis: schedules for intralesional treatment with sodium stibogluconate. Int J Dermatol. 1996;35(8):594–597.
   PubMed Web of Science ®Google Scholar
• Asilian A, Sadeghinia A, Faghihi G, et al. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime®) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime®) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol. 2004;43(4):281–283.
   PubMed Web of Science ®Google Scholar
• Salmanpour R, Handjani F, Nouhpisheh MK. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis. J Dermatolog Treat. 2001;12(3):159–162.
   PubMed Web of Science ®Google Scholar
• Miret J, Nascimento E, Sampaio W, et al. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine. 2008;26(12):1585–1594.
   PubMed Web of Science ®Google Scholar
• Santos DO, Coutinho CE, Madeira MF, et al. Leishmaniasis treatment—a challenge that remains: a review. Parasitol Res. 2008;103(1):1–10.
   PubMed Web of Science ®Google Scholar
• Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med. 1990;322(1):16–21.
   PubMed Web of Science ®Google Scholar
• Chulay JD, Spencer HC, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg. 1985;34(4):702–709.
   PubMed Web of Science ®Google Scholar
• Tanyuksel M, Bas AL, Araz E, et al. Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitro. Cell Biochem Funct. 2003;21(1):93–96.
   PubMed Web of Science ®Google Scholar
• Krolewiecki A, Leon S, Scott P, et al. Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg. 2002;67(3):273–277.
   PubMed Web of Science ®Google Scholar
• Teixeira AC, Paes MG, Guerra JdO, et al. Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Rev Inst Med Trop Sao Paulo. 2007;49(4):235–238.
   PubMedGoogle Scholar
• Layegh P, Yazdanpanah MJ, Vosugh EM, et al. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg. 2007;77(1):99–101.
   PubMed Web of Science ®Google Scholar
• Krolewiecki AJ, Romero HD, Cajal SP, et al. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg. 2007;77(4):640–646.
   PubMed Web of Science ®Google Scholar